Trial intelligence / Profile preview

Phase II dasatinib study in imatinib-resistant or -intolerant CML or Philadelphia chromosome-positive ALL

2006-001279-39Phase 2Completed

Sponsor

Bristol Myers Squibb

Start

Jul 2006

Modality

Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules

Countries

1